PBYI Puma Biotechnology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PBYI matters now
Puma Biotechnology, Inc. (PBYI) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.00 with +1.27% on the session and $407.2M in market capitalization; recent performance reads 1-month +11.01% and YTD +27.06%.
The latest financial table shown here is Q1 2026, with revenue of $44.8M, net income of $-3.8M, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E 11.41 and FCF yield 13.9%.
The latest indexable market news headline is "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Dorval Allison filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
11.41
PEG
4.35
P/B
2.99
P/S
1.69
EV/EBITDA
8.12
DCF Value
$17.07
FCF Yield
13.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.5%
Operating Margin
13.0%
Net Margin
10.7%
ROE
20.4%
ROA
12.7%
ROIC
17.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $44.8M | $-3.8M | $-0.07 |
| Q4 2025 | $75.5M | $13.4M | $0.26 |
| FY 2025 | $228.4M | $31.1M | $0.61 |
| Q3 2025 | $54.5M | $8.8M | $0.17 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.21
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.